This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Samadder, P. Articles by Arthur, G. Search for Related Content PubMed PubMed Citation Articles by Samadder, P. Articles by Arthur, G.

Decreased Sensitivity to 1-O-Octadecyl-2-O-methyl-glycerophosphocholine in MCF-7 Cells Adapted for Serum-free Growth Correlates with Constitutive Association of Raf-1 with Cellular Membranes¹

Department of Biochemistry and Molecular Biology, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0W3

We have previously shown that inhibition of MCF-7 cell proliferation by 1-O-octadecyl-2-O-methyl-glycerophosphocholine (ET-18-OCH₃) is linked to a drug-induced decrease in membrane Raf-1 levels and the subsequent inhibition of mitogen-activated protein (MAP) kinase activation in response to growth factor stimulation. We now report that adaptation of MCF-7 cells for growth in a serum-free formulation results in decreased sensitivity to growth inhibition by ET-18-OCH₃. The decrease in ET-18-OCH₃ sensitivity occurred progressively during the adaptation process and correlated with the presence of increasing amounts of inactive Raf-1 that stably associated with MCF-7 cell membranes. ET-18-OCH₃ sensitivity could be restored by growing the adapted cells in serum-containing medium, which resulted in the loss of membrane-associated Raf-1. In human normal mammary epithelial cells, which are insensitive to ET-18-OCH₃, Raf-1 was also associated with membranes in quiescent cells. In both cell types, incubation with ET-18-OCH₃ had no effect on the membrane-Raf-1 levels, suggesting that ET-18-OCH₃-induced reduction of Raf-1 levels in growth factor-stimulated MCF-7 cells is due to inhibition of Raf translocation. The activation and termination of the MAP kinase pathway in response to growth factors in the adapted MCF-7 cells and HNME cells occurred without changes to membrane Raf-1 levels. Because membrane translocation is not required to activate Raf in these cells, inhibition of Raf translocation by ET-18-OCH₃ subsequent to cell stimulation has no effect on the activation of the membrane-bound Raf and, consequently, the activation of the MAP kinase pathway. The ability of the cells to activate the MAP kinase pathway in the presence of the drugs enables them to resist the growth-inhibitory effects of the drug, leading to the observed ET-18-OCH₃ insensitivity of the cells.

This article has been cited by other articles:

				U. Kamasani, M. Huang, J. B. DuHadaway, E. V. Prochownik, P. S. Donover, and G. C. Prendergast Cyclin B1 Is a Critical Target of RhoB in the Cell Suicide Program Triggered by Farnesyl Transferase Inhibition Cancer Res., November 15, 2004; 64(22): 8389 - 8396. [Abstract] [Full Text] [PDF]

				A.-x. Liu, W. Du, J.-P. Liu, T. M. Jessell, and G. C. Prendergast RhoB Alteration Is Necessary for Apoptotic and Antineoplastic Responses to Farnesyltransferase Inhibitors Mol. Cell. Biol., August 15, 2000; 20(16): 6105 - 6113. [Abstract] [Full Text]